Inclusion Criteria

Inclusion criteria;

1. Female patients in whom continued administration of E7389 following the preceding
study will be useful.

2. Patients who have given written voluntary consent for participating in this study
before the completion of the preceding study.

3. Patients who have met the criteria for starting the next cycle in the preceding
study.

Namely, patients who meet all of the following criteria:

1. Neutrophil count >= 1,500 /µL

2. Platelet count >= 100,000 /µL

3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the
upper limit of normal (ULN) in the facility or <= 5 times ULN in patients with
hepatic metastasis)

4. Total bilirubin <= 1.5 times ULN

5. Serum creatinine <= 1.5 times ULN

6. Non-hematological toxicity <= Grade 2 (excluding disease-associated events and
laboratory abnormalities without clinical symptoms) Exclusion criteria;

Exclusion criteria:

1. Patients who are judged by the principal investigator or the other investigators to
be inappropriate as patients in this clinical study.

2. Pregnant women, nursing mothers, or premenopausal women of childbearing potential.
Premenopausal women of childbearing potential are defined as women who are <12 months
after the latest menstruation and are positive in pregnancy test performed for
enrollment or who have not taken the test and do not consent to take an appropriate
contraceptive measure. Post-menopausal women must be amenorrheic for at least 12
months to make sure that they have no potential for becoming pregnant.